PegBio says circular RNA-encoded GLP-1 candidate CR059 wins oral presentation slot at EASD 2026

• PegBio disclosed June 1, 2026 that preclinical findings for CR059 were accepted for EASD 2026 and selected for an oral discussion session.
• The results were previously selected as a late-breaking abstract for the ADA Scientific Sessions; the EASD presentation is scheduled for 2026.
• A single dose in non-human primates supported sustained drug exposure and prolonged body-weight reduction, suggesting potential for ultra-long-acting dosing.
• The program uses circular RNA to drive in-body production of a GLP-1 analogue, positioning it as a differentiated approach versus peptide GLP-1 drugs.
• CR059 remains in R&D, with clinical development and commercialization still uncertain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260601-12181471), on June 01, 2026, and is solely responsible for the information contained therein.